×
-1.80292950288577E-05 -0.000919494046469365 -0.000790713367692097 -0.000404371331360477 0.00126977749274309 0.00345904903195554 0.00487563649850475 0.00403856208645297
Stockreport

The Ratings Game: Biogen’s key Alzheimer’s disease drug is facing potential signs of trouble [MarketWatch]

ELI LILLY (LLY)  More Company Research Source: MarketWatch
Last eli lilly earnings: 7/24 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
PDF Biogen’s key Alzheimer’s disease drug is facing potential signs of trouble Biogen Inc.’s crucial Alzheimer’s disease drug aducanumab is still a year or two from releasing key clinical trial results, but the company’s latest news may leave some investors feeling more circumspect. Because the company saw “more variability on the primary endpoint than assumed,” Biogen BIIB, +0.94% decided to increase the sample size of two ongoing trials by about 255 patients each, Chief Medical Officer Alfred Sandrock said at a Leerink Partners conference on Wednesday. The change, done to maintain 90% statistical power for the study, won’t affect the study’s blinded nature, which refers to how neither patients nor doctors know which is the drug and which is the placebo, Sandrock said. He also suggested that the decision shouldn’t raise questions about the therapy’s effectiveness. Read: Biogen in promising but risky limelight after Eli Lilly’s Alzheimer’s drug fails “We don’t know the treatment eff [Read more]

IMPACT SNAPSHOT EVENT TIME: LLY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
LLY alerts
from News Quantified